Cadila Healthcare clarifies on getting permission to conduct phase III trial for two-dose Covid vaccine

The company confirms that they have got the permission for conduct of phase III trials for two-dose Covid vaccine.

Oct 05, 2021 01:10 IST India Infoline News Service

Cadila Healthcare Ltd on Tuedsday has clarified to the exchange on the news item regarding “Zydus Cadila gets permission to conduct phase III trial for two-dose Covid vaccine”.

Now, the company confirms that they have got the permission for conduct of phase III trials for two-dose Covid vaccine.

"We generally report all milestone events related to Covid vaccine, which can be price sensitive information. In this case, since we have already got emergency use authorisation for three-dose vaccine earlier (which is already informed to the stock exchanges vide our letter dated August 20 2021), we thought that giving information on completion of phase-III trials, when we apply for authorisation from the government would be right time for intimating to stock exchanges", said the company in a regulatory filing.

At around 1:41 PM, Cadila Healthcare was trading at Rs561.50 apiece down by Rs0.8 or 0.14% on Sensex.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity